PPT-Introduction to regulation of medicines and health technolo

Global context of drug regulation Dr Lembit Rägo Coordinator Quality Assurance and Safety Medicines Essential Medicines and Health Products World Health Organization Email ragolwhoint. To assist policy-makers and others, WHO and HAI are developing a series of reviews on pharmaceutical pricing policies and interventions, with a focus on low- and middle-income countries. . Five reviews have now been published on:. WHOon MedicinesNovember 2003World Health OrganizationGeneva urrently about 20% of countries have well devel-oped and operational medicines regulation. Ofthe rest approximately half have regulation of KNH/UON Pharmacy Symposium. Optimizing Medicine use to Improve Patient Outcome. . Dr. Fred . Siyoi. Deputy Registrar . 16. th. May 2014 . Introduction . Pharmacy and Poisons Board is the National Drug Regulatory Authority in Kenya established by Cap 244 laws of Kenya.. PARTNERSHIP. Medicines for Europe Vision 2020 . Our 5 pillars. 2. PATIENTS. Medicines For Europe . VISION. QUALITY. VALUE. SUSTAINABILITY. Pressure on EU budgets . Reduction. of . healthcare. . spending. Therapeutic Goods Administration. Overview. Why do we need regulation?. Who is Australia’s regulator?. How the TGA operates . Who works at the TGA. Therapeutic goods. Australian Register of Therapeutic Goods. By Laura Christian, Linda Collins, . Maythiwan. . Kiatgrajai. , . Agathe. Merle, . Nayantara. . Mukherji. , Alissa . Quade. Outline. Methodology. Overview. Definitions. Harmful Effects. Extent of the Problem. [INSERT DATE HERE]. [NAME OF PRESENTER]. [TITLE OF PRESENTER]. [COMPANY NAME]. Falsified medicines – a real problem. 2. The Pharmaceutical Journal, 5. th. June 2014. Why we need a Directive . Falsified products still being found in legitimate medicines supply chain – major risk to patient safety. IPC Meeting . 4 to 6 . June. 2014. Essential Medicines and Health Products Department (EMP) . . . October. 2013. . Office of the . [INSERT DATE HERE]. [NAME OF PRESENTER]. [TITLE OF PRESENTER]. [COMPANY NAME]. Falsified medicines – a real problem. 2. The Pharmaceutical Journal, 5. th. June 2014. Why we need a Directive . Falsified products still being found in legitimate medicines supply chain – major risk to patient safety. [INSERT DATE HERE]. [NAME OF PRESENTER]. [TITLE OF PRESENTER]. [COMPANY NAME]. Falsified medicines – a real problem. 2. The Pharmaceutical Journal, 5. th. June 2014. Why we need a Directive . Falsified products still being found in legitimate medicines supply chain – major risk to patient safety. Presented by . Deirdre Dimancesco. Department of Essential Medicines and . H. ealth Products, WHO. at the . Technical Briefing Seminar. 15 April, 2013 . MeTA. aim. MeTA aims at improving access to quality medicines by increasing transparency of the pharmaceutical sector through collection of reliable data, valid analysis, and then disclosure for advocacy and policy dialogue among stakeholders.. IPC Meeting . 4 to 6 . June. 2014. Essential Medicines and Health Products Department (EMP) . . . October. 2013. . Office of the . UKMi Horizon Scanning Working Group. Jim Glare. West Midlands Medicines Information Service. 11-Nov-2018. Objectives. This presentation aims to give some understanding of:. the ‘life-cycle’ of a medicine. Dr. Richard Torbett. Chief Economist, EFPIA. China/ EU Pharmaceutical Industry Forum. Shanghai, . 16 May 2015. Policy debate on health in recent years has been dominated by cost containment. Health & Growth.